Posted on 17/03/2010 in Medical Company Product News Boston Scientific has underlined the advantages of its Taxus stent technology by publishing positive results from a new clinical trial.
The medical device company's Taxus Express stents were trialled in a one-year study to establish their advantages over bare-metal stents in promoting heart health among diabetes patients.
It was found that Boston Scientific's devices were able to reduce the likelihood of ischemia-driven target lesion revascularisation and binary in-stent restenosis when compared to the control stents.
Dr Keith Dawkins, senior vice-president and chief medical officer for Boston Scientific, described these findings as being demonstrative of "impressive efficacy benefits".
He added: "This study provides important data to physicians regarding the use of drug-eluting stents in high-risk acute myocardial infarction patients, especially those with diabetes, during the early hours of a heart attack."
Last month, the company reported a year-on-year increase in sales revenue during the final fiscal quarter of 2009, with strong coronary stent sales cited as a contributing factor.Other news stories from 17/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
